Precipio Reminds Shareholders to Vote Before the Annual General Meeting on June 15, 2018
June 14 2018 - 12:19PM
Specialty diagnostics company Precipio, Inc. (NASDAQ:PRPO), today
reminded its shareholders to vote on proposals 1-6 in accordance
with the recommendations of the Board, as set out in the proxy
material previously mailed to the shareholders on or about June 5,
2018, for the Company's upcoming Annual General
Meeting which will be held
TOMORROW, June 15,
2018 at 9:30am Eastern Standard Time at the Company’s office
in New Haven.
Your Participation is Important — Please
Vote Today!
We kindly request that you vote your shares by proxy following
the methods as instructed by the notice:
VOTE BY INTERNET - www.proxyvote.com Use the Internet to
transmit your voting instructions and for electronic delivery of
information. Vote by 11:59 p.m. Eastern Time on June 14, 2018. Have
your proxy card in hand when you access the web site and follow the
instructions to obtain your records and to create an electronic
voting instruction form.
VOTE BY PHONE - 1-800-690-6903Use any touch-tone telephone to
transmit your voting instructions. Vote by 11:59 p.m. Eastern Time
on June 14, 2018. Have your proxy card in hand when you call and
then follow the instructions.
If you require additional information such as your
control number in order to vote, please contact
your broker to receive the necessary information. For further
assistance you can also contact Precipio at
investors@precipiodx.com.
If you have already voted, you do not
need to do anything further and we thank you for your
support.
About Precipio
Precipio has built a platform designed to eradicate the problem
of misdiagnosis by harnessing the intellect, expertise and
technology developed within academic institutions and delivering
quality diagnostic information to physicians and their patients
worldwide. Through its collaborations with world-class academic
institutions specializing in cancer research, diagnostics and
treatment such as the Yale School of Medicine and Harvard’s
Dana-Farber Cancer Institute, Precipio offers a new standard of
diagnostic accuracy enabling the highest level of patient care. For
more information, please visit www.precipiodx.com.
Forward-Looking Statements
Certain statements in this press release constitute
“forward-looking statements,” within the meaning of federal
securities laws, including statements related to ICP technology,
including other financial projections and potential market
opportunity, plans and prospects and other statements containing
the words “anticipate,” “intend,” “may,” “plan,” “predict,” “will,”
“would,” “could,” “should,” and similar expressions, constitute
forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. The Company's actual
results could differ materially from those anticipated in these
forward-looking statements as a result of various factors. Factors
that could cause future results to materially differ from the
recent results or those projected in forward-looking statements
include the known risks, uncertainties and other factors described
in the Company’s quarterly report on form 10-Q for the
quarter ended March 31, 2018 and on the Annual Report on Form 10-K
for the year ended December 31, 2017, the Company’s prior filings
and from time to time in the Company’s subsequent filings with the
Securities and Exchange Commission. Any change in such factors,
risks and uncertainties may cause the actual results, events and
performance to differ materially from those referred to in such
statements. All information in this press release is as of the date
of the release and the Company does not undertake any duty to
update this information, including any forward-looking statements,
unless required by law.
Additional Information and where to find
it
The Company has filed a definitive proxy
statement and associated proxy card with the U.S. Securities and
Exchange Commission (the “SEC”) in connection with the solicitation
of proxies for the Annual Meeting of Shareholders of the Company
(the “Annual Meeting”) on May 29, 2018. The Company, its directors,
its executive officers and certain other individuals set forth in
the definitive proxy statement will be deemed participants in the
solicitation of proxies from shareholders in respect of the Annual
Meeting. Information regarding the names of the Company’s directors
and executive officers and certain other individuals and their
respective interests in the Company by security holdings or
otherwise is set forth in the Company’s quarterly report on form
10-Q for the quarter ended March 31, 2018 and on the Annual Report
on Form 10-K for the year ended December 31, 2017, has been
included in the definitive proxy statement filed with the SEC on
May 29, 2019. Details containing the nominees of the Company’s
Board of Directors for election at the 2018 Annual Meeting of
Shareholders are included in the definitive proxy statement. BEFORE
MAKING ANY VOTING DECISION, SHAREHOLDERS OF THE COMPANY ARE URGED
TO READ ALL RELEVANT DOCUMENTS FILED WITH OR FURNISHED TO THE SEC,
INCLUDING THE DEFINITIVE PROXY STATEMENT AND ANY SUPPLEMENTS
THERETO AND ACCOMPANYING PROXY CARD, BECAUSE THEY CONTAIN IMPORTANT
INFORMATION. The Company’s definitive proxy statement and a form of
proxy have been mailed to shareholders of the Company. Investors
and shareholders can obtain a copy of the documents filed by the
Company with the SEC, including the definitive proxy statement,
free of charge by visiting the SEC’s website, www.sec.gov. The
Company’s shareholders can also obtain, without charge, a copy of
the definitive proxy statement and other relevant filed documents
when available from the Company’s website at
www.precipiodx.com.
Inquiries:
investors@precipiodx.com
+1-203-787-7888
Precipio (NASDAQ:PRPO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Precipio (NASDAQ:PRPO)
Historical Stock Chart
From Apr 2023 to Apr 2024